Merck KGaA : Merck KGaA CMD feedback: Growth to revive in 2019 after transition year in 2018
>Merck confirms its outlook for 2018 and growth prospects for 2019 - Merck confirmed its expectations for 2018, i.e. EBITDA pre (= EBITDA pre one-offs) down 1e1 to -3% yoy mainly due to FX headwinds offsetting the H2 vs H1 acceleration of organic growth in Healthcare, and ongoing strong organic growth in Life Science (LS). After a year of transition in 2018, Merck plans to return to sustainable sales and EBITDA pre growth in 2019 driven by Healthcare and LS, while Perf...Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.